Trial Profile

An Open-Label Treatment of ZX008 (Fenfluramine Hydrochloride) in Pediatric and Adult Epilepsy Patients (Ages 4-25) With Sunflower Syndrome

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fenfluramine (Primary)
Indications Absence epilepsy; Epilepsy; Generalised seizures; Reflex epilepsy; Tonic-clonic epilepsy
Focus Therapeutic Use

Most Recent Events

06 Nov 2024 Status changed from active, no longer recruiting to completed.
22 Jun 2023 Results assessing long-term results for an initial cohort of patients with Sunflower syndrome who enrolled in an open-label study of low-dose fenfluramine as well as the short-term results of a second cohort, published in the Developmental Medicine and Child Neurology.
16 Sep 2022 Planned End Date changed from 1 Feb 2020 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com